Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2000

View Archived Issues

Oncolym development plans clarified

Dyax and Human Genome Sciences enter drug discovery agreement

AutoImmune sells rights to patent applications in Alzheimer's disease

GPC to acquire Mitotix in an all-share transaction

New study of Sandostatin for managing diarrhea to commence in the U.S. and Canada

Genzyme Transgenics expands agreement with Centocor for second monoclonal antibody

Inhibitex commences phase I/II clinical testing of treatment for S. aureus infections

Depression and anxiety, significant risk factors for hypertension

Dopamine D1 agonist improves working memory in nonhuman primate model

IND submitted by Atrix for 120-day leuprolide treatment for prostate cancer

Phase I clinical study to begin with Reolysin as cancer treatment

Hydroxamic acid-based MMP inhibitors developed at Pfizer

BASF describes new endothelin receptor antagonists and their use

Hokuriku Seiyaku scientists discover new cytokine inhibitors

Anti-HBV nucleosides designed by Korean research team

Heterocyclic leukocyte adhesion inhibitors in early development at Aventis

Schering-Plough's new H3 receptor antagonists particularly useful for allergy

Orally bioavailable gpIIb/IIIa receptor antagonist ME-3230 profiled at Japanese meeting

Kotobuki's new hypouricemic agent KT-651 inhibits biosynthesis, enhances excretion of uric acid

Siga acquires Chlamydia vaccine technology from Oregon State University

Potent and selective PDE5 inhibitor may be useful in erectile dysfunction, heart failure

Dual ACAT-inhibitory/antioxidant effects of KY-455 may be advantageous in atherosclerosis

Design of new, nonpeptide MMP inhibitors reported by Pharmacia & Upjohn at ACS meeting

ACS presentation for AMP-397A, a broad-spectrum anticonvulsant with a novel mechanism of action

AxyS and Cytovia collaborate on development of anticancer agents

Monsanto and Pharmacia & Upjohn shareholders vote to approve merger

MC-002434 identified as prototype efflux pump inhibitor for potentiating levofloxacin activity

CPMP recommends approval of Kogenate Bayer as hemophilia A treatment